

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

<u>NEWS 1</u>		Web Page for STN Seminar Schedule - N. America
<u>NEWS 2</u>	APR 02	CAS Registry Number Crossover Limits Increased to 500,000 in Key STN Databases
<u>NEWS 3</u>	APR 02	PATDPAFULL: Application and priority number formats enhanced
<u>NEWS 4</u>	APR 02	DWPI: New display format ALLSTR available
<u>NEWS 5</u>	APR 02	New Thesaurus Added to Derwent Databases for Smooth Sailing through U.S. Patent Codes
<u>NEWS 6</u>	APR 02	EMBASE Adds Unique Records from MEDLINE, Expanding Coverage back to 1948
<u>NEWS 7</u>	APR 07	50,000 World Traditional Medicine (WTM) Patents Now Available in CAplus
<u>NEWS 8</u>	APR 07	MEDLINE Coverage Is Extended Back to 1947
<u>NEWS 9</u>	JUN 16	WPI First View (File WPIFV) will no longer be available after July 30, 2010
<u>NEWS 10</u>	JUN 18	DWPI: New coverage - French Granted Patents
<u>NEWS 11</u>	JUN 18	CAS and FIZ Karlsruhe announce plans for a new STN platform
<u>NEWS 12</u>	JUN 18	IPC codes have been added to the INSPEC backfile (1969-2009)
<u>NEWS 13</u>	JUN 21	Removal of Pre-IPC 8 data fields streamline displays in CA/CAplus, CASREACT, and MARPAT
<u>NEWS 14</u>	JUN 21	Access an additional 1.8 million records exclusively enhanced with 1.9 million CAS Registry Numbers -- EMBASE Classic on STN
<u>NEWS 15</u>	JUN 28	Introducing "CAS Chemistry Research Report": 40 Years of Biofuel Research Reveal China Now Atop U.S. in Patenting and Commercialization of Bioethanol
<u>NEWS 16</u>	JUN 29	Enhanced Batch Search Options in DGENE, USGENE, and PCTGEN
<u>NEWS 17</u>	JUL 19	Enhancement of citation information in INPADOC databases provides new, more efficient competitor analyses
<u>NEWS 18</u>	JUL 26	CAS coverage of global patent authorities has expanded to 61 with the addition of Costa Rica
<u>NEWS 19</u>	SEP 15	MEDLINE Cited References provide additional relevant records with no additional searching.
<u>NEWS 20</u>	OCT 04	Removal of Pre-IPC 8 data fields streamlines displays in USPATFULL, USPAT2, and USPATOLD.
<u>NEWS 21</u>	OCT 04	Precision of EMBASE searching enhanced with new chemical name field
<u>NEWS 22</u>	OCT 06	Increase your retrieval consistency with new formats or for Taiwanese application numbers in CA/CAplus.
<u>NEWS 23</u>	OCT 21	CA/CAplus kind code changes for Chinese patents increase consistency, save time
<u>NEWS 24</u>	OCT 22	New version of STN Viewer preserves custom highlighting of terms when patent documents are saved in .rtf format
<u>NEWS 25</u>	OCT 28	INPADOCDB/INPAFAMDB: Enhancements to the US national patent classification.
<u>NEWS 26</u>	NOV 03	New format for Korean patent application numbers in CA/CAplus increases consistency, saves time.
<u>NEWS 27</u>	NOV 04	Selected STN databases scheduled for removal on December 31, 2010
<u>NEWS 28</u>	NOV 18	PROUSDDR and SYNTHLINE Scheduled for Removal December 31, 2010 by Request of Prous Science
<u>NEWS 29</u>	NOV 22	Higher System Limits Increase the Power of STN Substance-Based Searching

NEWS 30 NOV 22 Enjoy a free month of INPADOCDB/INPAFAMDB SDIs!  
NEWS 31 NOV 24 Search an additional 46,850 records with MEDLINE  
 backfile extension to 1946

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,  
 AND CURRENT DISCOVER FILE IS DATED 07 JULY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 21:27:31 ON 01 DEC 2010

=> file caplus biosis

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'CAPLUS' ENTERED AT 21:27:44 ON 01 DEC 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 21:27:44 ON 01 DEC 2010

Copyright (c) 2010 The Thomson Corporation

=> OX40 (L) DNA (w) vaccine

L1 3 OX40 (L) DNA (W) VACCINE

=> D L1 IBIS ABS 1-3

L1 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER:	2007:859817 CAPLUS
DOCUMENT NUMBER:	147:298670
TITLE:	Enhanced protective efficacy and reduced viral load of foot-and-mouth disease DNA vaccine with co-stimulatory molecules as the molecular adjuvants
AUTHOR(S):	Xiao, Chong; Jin, Huali; Hu, Yanxin; Kang, Youmin; Wang, Junpeng; Du, Xiaogang; Yang, Yu; She, Ruiping; Wang, Bin
CORPORATE SOURCE:	State Key Laboratory for Agro-Biotechnology, Key Laboratory of Agro-Microbial Resources and Applications of MOA, China Agricultural University, Beijing, 100094, Peop. Rep. China
SOURCE:	Antiviral Research (2007), 76(1), 11-20 CODEN: ARSRDR; ISSN: 0166-3542
PUBLISHER:	Elsevier B.V.

DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB To improve efficacy of DNA vaccination, various approaches have been developed, including the use of plasmid expressing co-stimulatory mols. as mol. adjuvants. Here, the authors investigated whether co-inoculation of a construct expressing either 4-1BBL or OX40L as the mol. adjuvant with FMDV DNA vaccine, pcD-VP1, can increase immune responses and protective efficacies. Compared to the group immunized with pcD-VP1 alone, the co-inoculation of either mol. adjuvant induced a higher ratio of IgG2a/IgG1, higher levels of expression of IFN- $\gamma$  in CD4+ and CD8+ T cells and antigen-specific CTL responses, and more importantly provided an enhanced protection against the live FMDV challenge in animals. Concurrently, 4-1BBL as the mol. adjuvant dramatically reduced the viral loads of FMDV in vivo after the challenge. Thus, co-stimulatory mols. 4-1BBL and OX40L can enhance the antigen-specific cell-mediated responses elicited by VP1 DNA vaccine and provide an enhanced protective efficacy with the reduced viral loads.

OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN



ACCESSION NUMBER: 2001:313168 CAPLUS  
 TITLE: Papers to Appear in Forthcoming Issues  
 AUTHOR(S): Anon  
 SOURCE: Cellular Immunology (2001), 208(2), 148  
 CODEN: CLIMB8; ISSN: 0008-8749  
 PUBLISHER: Academic Press  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB (Received and Accepted Dates Follow Title)Mice Disrupted for the KvLQT1 Potassium Channel Regulator IsK Gene Accumulate Mature T Cells. Dominique Chabannes, Jacques Barhanin, and Denis Escande. (Received 9/27/00; accepted 3/7/01.)Pos. and Neg. Consequences of Sol. Fas Ligand Produced by an Antigen-Specific CD4+ T Cell Response in Human Carcinoma Immune Interactions. Elke S. Bergmann-Leitner and Scott I. Abrams. (Received 12/18/00; accepted 3/7/01.)Mol. Cloning and Expression Pattern of Porcine Myeloid DAP12-Assocg. Lectin-1. Daesong Yim, Hyun-Bae Jie, John Sotiriadis, Yoon-Sang Kim, and Yoon B. Kim. (Received 12/13/00; accepted 3/4/01.)**OX40** Ligation Enhances Cell Cycle Turnover of Ag-Activated CD4 T Cells in Vivo. Amy R. Weatherill, Joseph R. Maxwell, Chikara Takahashi, Andrew D. Weinberg, and Anthony T. Vella. (Received 1/23/01; accepted 3/10/01.)Codelivery of DNA Coding for the Sol. Form of CD86 Results in the Down-Regulation of the Immune Response to **DNA Vaccines**. Juan Flo, Sergio Tisminetzky, and Francisco Baralle. (Received 10/23/00; accepted 3/18/01.)Dendritic Cells Issued in Vitro from Bone Marrow Produce PGE2 That Contributes to the Immunomodulation Induced by Antigen-Presenting Cells. H. Harizi, M. Juzan, C. Grosset, M. Rashedi, and N. Gualde. (Received 11/24/00; accepted 3/15/01.)A "Chimeric" C57L-Derived Ly49 Inhibitory Receptor Resembling the Ly49D Activation Receptor. Indira K. Mehta, Hamish R. C. Smith, Jian Wang, David H. Margulies, and Wayne M. Yokoyama. (Received 1/17/01; accepted 3/14/01.)Idiotypic-Anti-idiotypic B Cell Interactions Generated against a Protective Antigen of a Morbillivirus in Mice. Shibani Mitra-Kaushik, M. S. Shaila, Anjali Karanade, and Rabindranath Nayak. (Received 10/16/00; accepted 3/22/01.).  
 (c) 2001 Academic Press.

L1 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN



ACCESSION NUMBER: 1998:684978 CAPLUS  
 DOCUMENT NUMBER: 129:274700  
 ORIGINAL REFERENCE NO.: 129:56017a,56020a  
 TITLE: DNA encoding targeting protein fused to antigen or epitope in enhancement of immune response to DNA vaccines  
 INVENTOR(S): Boyle, Jefferey Stephen; Brady, Jamie Louise; Lew, Andrew Mark  
 PATENT ASSIGNEE(S): The Council of the Queensland Institute of Medical Research, Australia; Commonwealth Scientific and Industrial Research Organisation; The University of Melbourne; The Walter and Eliza Hall Institute of Medical Research; CSL Ltd.  
 SOURCE: PCT Int. Appl., 64 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 9844129</u>	A1	19981008	<u>WO 1998-AU208</u>	19980326
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
<u>CA 2285692</u>	A1	19981008	<u>CA 1998-2285692</u>	19980326
<u>AU 9864902</u>	A	19981022	<u>AU 1998-64902</u>	19980326
<u>AU 728962</u>	B2	20010125		
<u>EP 972054</u>	A1	20000119	<u>EP 1998-910530</u>	19980326
<u>EP 972054</u>	B1	20081210		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
<u>NZ 500151</u>	A	20010126	<u>NZ 1998-500151</u>	19980326
<u>JP 2001522235</u>	T	20011113	<u>JP 1998-540989</u>	19980326
<u>JP 4382163</u>	B2	20091209		
<u>AT 417112</u>	T	20081215	<u>AT 1998-910530</u>	19980326
<u>ZA 9802608</u>	A	19981008	<u>ZA 1998-2608</u>	19980327
<u>US 20030035793</u>	A1	20030220	<u>US 2002-185318</u>	20020628
<u>US 7423016</u>	B2	20080909		
<u>US 20030072742</u>	A1	20030417	<u>US 2002-185799</u>	20020628
<u>US 7423023</u>	B2	20080909		
<u>CA 2489940</u>	A1	20060608	<u>CA 2004-2489940</u>	20041208
PRIORITY APPLN. INFO.:			<u>AU 1997-5891</u>	A 19970327
			<u>AU 1998-1830</u>	A 19980213
			<u>WO 1998-AU208</u>	W 19980326
			<u>US 2000-402020</u>	A1 20000328

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention provides methods of enhancing the immune response to an immunogen and to compns. for use in these methods. In particular the present invention provides a DNA mol. for use in raising an immune response to an antigen. The DNA mol. includes a first sequence encoding a

targeting mol., a second sequence encoding the antigen or an epitope thereof, and optionally a third sequence encoding a polypeptide which promotes dimerization or multimerization of the product encoded by the DNA mol. Immunization of mice with a no. of DNA sequences encoding

CTLA4-antigen fusions enhanced the immune response to the antigen.

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> antigen (1) OX40

L2 600 ANTIGEN (L) OX40

=> DNA (w) vaccine

L3 12679 DNA (W) VACCINE

=> L2 and L3

L4 4 L2 AND L3

=> D L4 IBIB ABS 1-4

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN



ACCESSION NUMBER: 2007:859817 CAPLUS

DOCUMENT NUMBER: 147:298670

TITLE: Enhanced protective efficacy and reduced viral load of foot-and-mouth disease **DNA vaccine** with co-stimulatory molecules as the molecular adjuvants

AUTHOR(S): Xiao, Chong; Jin, Huali; Hu, Yanxin; Kang, Youmin; Wang, Junpeng; Du, Xiaogang; Yang, Yu; She, Ruiping; Wang, Bin

CORPORATE SOURCE: State Key Laboratory for Agro-Biotechnology, Key Laboratory of Agro-Microbial Resources and Applications of MOA, China Agricultural University, Beijing, 100094, Peop. Rep. China

SOURCE: Antiviral Research (2007), 76(1), 11-20  
CODEN: ARSRDR; ISSN: 0166-3542

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB To improve efficacy of DNA vaccination, various approaches have been developed, including the use of plasmid expressing co-stimulatory mols. as mol. adjuvants. Here, the authors investigated whether co-inoculation of a construct expressing either 4-1BBL or OX40L as the mol. adjuvant with FMDV **DNA vaccine**, pcD-VP1, can increase immune responses and protective efficacies. Compared to the group immunized with pcD-VP1 alone, the co-inoculation of either mol. adjuvant induced a higher ratio of IgG2a/IgG1, higher levels of expression of IFN- $\gamma$  in CD4+ and CD8+ T cells and antigen-specific CTL responses, and more importantly provided an enhanced protection against the live FMDV challenge in animals. Concurrently, 4-1BBL as the mol. adjuvant dramatically reduced the viral loads of FMDV in vivo after the challenge. Thus, co-stimulatory mols. 4-1BBL and OX40L can enhance the antigen-specific cell-mediated responses elicited by VP1 **DNA vaccine** and provide an enhanced protective efficacy with the reduced viral loads.

OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN



ACCESSION NUMBER: 2004:1156439 CAPLUS  
 DOCUMENT NUMBER: 142:73408  
 TITLE: **DNA vaccines** comprising immunomodulatory proteins and antigen from pathogens  
 INVENTOR(S): Weiner, David B.; Muthumani, Karuppiiah; Kutzler, Michele; Choo, Andrew K.; Chattergoon, Michael A.  
 PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, USA  
 SOURCE: PCT Int. Appl., 47 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 2004112706</u>	A2	20041229	<u>WO 2004-US19028</u>	20040614
<u>WO 2004112706</u>	A3	20050414		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
<u>AU 2004249191</u>	A1	20041229	<u>AU 2004-249191</u>	20040614
<u>CA 2529051</u>	A1	20041229	<u>CA 2004-2529051</u>	20040614
<u>EP 1633372</u>	A2	20060315	<u>EP 2004-755303</u>	20040614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
<u>JP 2007502868</u>	T	20070215	<u>JP 2006-533794</u>	20040614
<u>US 20070104686</u>	A1	20070510	<u>US 2004-560653</u>	20040614
<u>PRIORITY APPLN. INFO.:</u>				
			<u>US 2003-478187P</u>	P 20030613
			<u>US 2003-478230P</u>	P 20030613
			<u>US 2003-478250P</u>	P 20030613
			<u>WO 2004-US19028</u>	W 20040614

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The authors disclose the use of recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid mols. that encode an immunogen in combination with an isolated nucleic acid mol. that encodes an immunomodulator protein selected from the group consisting of: Fos, c-jun, Sp-1, AP-1, AP-2, p38, p65Rel, MyD88, IRAK, TRAF6, IκB, inactive NIK, SAP kinase, SAP-1, JNK, interferon response genes, NF-κB, Bax, TRAIL, TRAIL receptors, DcR5, TRAIL-R3, TRAIL-R4, RANK, RANK ligand, Ox40, Ox40 ligand, NKG2D, MICA, MICB, NKG2A, NKG2B, NKG2C, NKG2E, NKG2F, TAP1, TAP2 and functional fragments thereof.

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)  
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN



ACCESSION NUMBER: 2001:313168 CAPLUS  
 TITLE: Papers to Appear in Forthcoming Issues  
 AUTHOR(S): Anon  
 SOURCE: Cellular Immunology (2001), 208(2), 148  
 CODEN: CLIMB8; ISSN: 0008-8749  
 PUBLISHER: Academic Press  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB (Received and Accepted Dates Follow Title)Mice Disrupted for the KvLQT1 Potassium Channel Regulator IsK Gene Accumulate Mature T Cells. Dominique Chabannes, Jacques Barhanin, and Denis Escande. (Received 9/27/00; accepted 3/7/01.)Pos. and Neg. Consequences of Sol. Fas Ligand Produced by an **Antigen**-Specific CD4+ T Cell Response in Human Carcinoma Immune Interactions. Elke S. Bergmann-Leitner and Scott I. Abrams. (Received 12/18/00; accepted 3/7/01.)Mol. Cloning and Expression Pattern of Porcine Myeloid DAP12-Assocg. Lectin-1. Daesong Yim, Hyun-Bae Jie, John Sotiriadis, Yoon-Sang Kim, and Yoon B. Kim. (Received 12/13/00; accepted 3/4/01.)**Ox40** Ligation Enhances Cell Cycle Turnover of Ag-Activated CD4 T Cells in Vivo. Amy R. Weatherill, Joseph R. Maxwell, Chikara Takahashi, Andrew D. Weinberg, and Anthony T. Vella. (Received 1/23/01; accepted 3/10/01.)Codelivery of DNA Coding for the Sol. Form of CD86 Results in the Down-Regulation of the Immune Response to **DNA Vaccines**. Juan Flo, Sergio Tisminetzky, and Francisco Baralle. (Received 10/23/00; accepted 3/18/01.)Dendritic Cells Issued in Vitro from Bone Marrow Produce PGE2 That Contributes to the Immunomodulation Induced by **Antigen**-Presenting Cells. H. Harizi, M. Juzan, C. Grosset, M. Rashedi, and N. Gualde. (Received 11/24/00; accepted 3/15/01.)A "Chimeric" C57L-Derived Ly49 Inhibitory Receptor Resembling the Ly49D Activation Receptor. Indira K. Mehta, Hamish R. C. Smith, Jian Wang, David H. Margulies, and Wayne M. Yokoyama. (Received 1/17/01; accepted 3/14/01.)Idiotypic-Anti-idiotypic B Cell Interactions Generated against a Protective **Antigen** of a Morbillivirus in Mice. Shibani Mitra-Kaushik, M. S. Shaila, Anjali Karanade, and Rabindranath Nayak. (Received 10/16/00; accepted 3/22/01.).  
 (c) 2001 Academic Press.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN



ACCESSION NUMBER: 1998:684978 CAPLUS  
 DOCUMENT NUMBER: 129:274700  
 ORIGINAL REFERENCE NO.: 129:56017a,56020a  
 TITLE: DNA encoding targeting protein fused to antigen or epitope in enhancement of immune response to **DNA vaccines**  
 INVENTOR(S): Boyle, Jefferey Stephen; Brady, Jamie Louise; Lew, Andrew Mark  
 PATENT ASSIGNEE(S): The Council of the Queensland Institute of Medical Research, Australia; Commonwealth Scientific and Industrial Research Organisation; The University of Melbourne; The Walter and Eliza Hall Institute of Medical Research; CSL Ltd.  
 SOURCE: PCT Int. Appl., 64 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 9844129</u>	A1	19981008	<u>WO 1998-AU208</u>	19980326
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
<u>CA 2285692</u>	A1	19981008	<u>CA 1998-2285692</u>	19980326
<u>AU 9864902</u>	A	19981022	<u>AU 1998-64902</u>	19980326
<u>AU 728962</u>	B2	20010125		
<u>EP 972054</u>	A1	20000119	<u>EP 1998-910530</u>	19980326
<u>EP 972054</u>	B1	20081210		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
<u>NZ 500151</u>	A	20010126	<u>NZ 1998-500151</u>	19980326
<u>JP 2001522235</u>	T	20011113	<u>JP 1998-540989</u>	19980326
<u>JP 4382163</u>	B2	20091209		
<u>AT 417112</u>	T	20081215	<u>AT 1998-910530</u>	19980326
<u>ZA 9802608</u>	A	19981008	<u>ZA 1998-2608</u>	19980327
<u>US 20030035793</u>	A1	20030220	<u>US 2002-185318</u>	20020628
<u>US 7423016</u>	B2	20080909		
<u>US 20030072742</u>	A1	20030417	<u>US 2002-185799</u>	20020628
<u>US 7423023</u>	B2	20080909		
<u>CA 2489940</u>	A1	20060608	<u>CA 2004-2489940</u>	20041208
PRIORITY APPLN. INFO.:				
			<u>AU 1997-5891</u>	A 19970327
			<u>AU 1998-1830</u>	A 19980213
			<u>WO 1998-AU208</u>	W 19980326
			<u>US 2000-402020</u>	A1 20000328

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention provides methods of enhancing the immune response to an immunogen and to compns. for use in these methods. In particular the present invention provides a DNA mol. for use in raising an immune response to an antigen. The DNA mol. includes a first sequence encoding a targeting mol., a second sequence encoding the antigen or an epitope thereof, and optionally a third sequence encoding a polypeptide which promotes dimerization or multimerization of the product encoded by the DNA mol. Immunization of mice with a no. of DNA sequences encoding CTLA4-antigen fusions enhanced the immune response to the antigen.

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>